COLORADO SPRINGS, Colo., April 4, 2014 /PRNewswire/ -- Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting is proud to announce plans to enter the State of Nevada where new law expands medical cannabis opportunities to research, grows, and dispensaries. As the Company has created a partnership in Michigan to advance state cannabis law and pursue state-wide initiatives in Michigan, Cannabis Science intends to bring its know how and resources to Nevada, the state of Cannabis Science's Incorporation.
The new law marks another milestone in the progression in the legalization process of the medical cannabis industry in the United States -- one that is aimed at ways of managing multiple ailments for patients. In addition, the new law is expected to contribute to the creation of new sources of revenue and employment opportunities within the state. Cannabis Science is well positioned to bring novel patient-based initiatives to Nevada.
"Nevada is another key state in which we, as Nevada incorporate company, can deliver cannabis-based products and medical care to patients. As Nevada legislation continues to develop, our Michigan state-based experience puts Cannabis Science in an advantageous position to develop new opportunities in Nevada," stated Dr. Dorothy Bray, Director and CEO of Cannabis Science, Inc.
Nevada originally introduced their medical cannabis program on a patient level in 2001. The new law, effective as of April 1, 2014, allows for the buying, selling, and testing of cannabis as regulated, and the taxation of cannabis revenues. Licenses for these types of businesses will be issued, and patients can expect doors to open around January 1, 2015.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Robert Kane, CFO & Director
SOURCE Cannabis Science, Inc.